Literature DB >> 20547306

Hepatocellular carcinoma: New and emerging risks.

Morris Sherman1.   

Abstract

The underlying liver diseases that put patients at risk for the development of hepatocellular carcinoma (HCC) are well known. However, it is equally well known that not all patients with these conditions will develop HCC. Therefore within the disease groups (hepatitis B, cirrhosis, etc.,) there are other factors that indicate greater or lesser risk. Some markers of risk are common to all causes of HCC, such as cellular dysplasia, advancing age and male gender. Others factors are specific to individual diseases. This has been well established for hepatitis B in which viral load, genotype and antigen status are major contributors to increased risk of HCC. For both hepatitis B and hepatitis C attempts have been made to identify those individuals at greatest risk using data from large cohort studies. In addition to the common causes of liver disease that are recognized to be causes of HCC non-alcoholic fatty liver disease and possibly diabetes are newly emerging risk factors. Copyright 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20547306     DOI: 10.1016/S1590-8658(10)60508-7

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  8 in total

1.  Platelet-related phenotypic patterns in hepatocellular carcinoma patients.

Authors:  Brian I Carr; Chih-Yun Lin; Sheng-Nan Lu
Journal:  Semin Oncol       Date:  2014-04-23       Impact factor: 4.929

2.  UPLC-MS-based urine metabolomics reveals indole-3-lactic acid and phenyllactic acid as conserved biomarkers for alcohol-induced liver disease in the Ppara-null mouse model.

Authors:  Soumen K Manna; Andrew D Patterson; Qian Yang; Kristopher W Krausz; Jeffrey R Idle; Albert J Fornace; Frank J Gonzalez
Journal:  J Proteome Res       Date:  2011-07-28       Impact factor: 4.466

3.  Loss of expression of MHC class I-related chain A (MICA) is a frequent event and predicts poor survival in patients with hepatocellular carcinoma.

Authors:  Jie Zhang; Zhuding Xu; Xingchun Zhou; Haibin Zhang; Ning Yang; Yousheng Wu; Yibing Chen; Guangshun Yang; Tingting Ren
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

Review 4.  Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma.

Authors:  Caecilia H C Sukowati; Korri E El-Khobar; Susan I Ie; Beatrice Anfuso; David H Muljono; Claudio Tiribelli
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

5.  ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B.

Authors:  Qiang Li; Cui-Hua Yu; Jin-Hong Yu; Li Liu; Shuang-Shuang Xie; Wen-Wen Li; Xia Yang; Wen-Bo Fan; Zhong-Tao Gai; Shi-Jun Chen; Naoya Kato
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

Review 6.  Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines.

Authors:  Ayman A Abdo; Mazen Hassanain; AbdulRahman AlJumah; Ashwaq Al Olayan; Faisal M Sanai; Hamad A Alsuhaibani; Huda Abdulkareem; Khalid Abdallah; Mohammad AlMuaikeel; Mohammad Al Saghier; Mohammad Babatin; Monther Kabbani; Shouki Bazarbashi; Peter Metrakos; Jordi Bruix
Journal:  Ann Saudi Med       Date:  2012 Mar-Apr       Impact factor: 1.526

7.  Enhanced effectivity of an ALK5-inhibitor after cell-specific delivery to hepatic stellate cells in mice with liver injury.

Authors:  Marike Marjolijn van Beuge; Jai Prakash; Marie Lacombe; Eduard Post; Catharina Reker-Smit; Leonie Beljaars; Klaas Poelstra
Journal:  PLoS One       Date:  2013-02-18       Impact factor: 3.752

8.  Regulation of the expression of the liver cancer susceptibility gene MICA by microRNAs.

Authors:  Takahiro Kishikawa; Motoyuki Otsuka; Takeshi Yoshikawa; Motoko Ohno; Akemi Takata; Chikako Shibata; Yuji Kondo; Masao Akanuma; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.